GSK Cancer Vaccine Fails in Melanoma Late-Stage Trial

The company says it will continue with the Phase III trial of its MAGE-A3 therapeutic vaccine to see if it benefited a subset of patients
Sept. 6, 2013
An experimental cancer vaccine from GlaxoSmithKline failed to help melanoma patients in a closely watched late-stage clinical trial, dealing a blow to the high-risk, high-reward project. Read the full story
Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates

Related

Eli Lilly’s new Concord, North Carolina site was built with NASCAR-like speed
Celltrion to buy US biologics manufacturing plant as part of tariff response strategy
OnTrak Wireless: Total Bearing Health Solution
Sponsored
OnTrak Wireless & UltraTrak Vario Lubricators: Bearing Health Unified
Sponsored